Of note, the promoter methylation of OC2 is downregulated with grade (Supplementary Fig. 2C) suggesting that decreased methylation levels of OC2 might be an underlying indicator which reflects clinical characteristics of BC patients. Here, ONECUT2 is linked to breast cancer.